Keep Mosquitoes and More Out of Your Yard with Garlic From Garlic Research ...(Mosquito Barrier was proven to be effect...),Health

Date:6/30/2009

Mosquito Barrier was proven to be effective against both Anopheles and Culex adult mosquitoes. Mosquito Barrier achieved a mortality rate of over 90% after 24 hours of exposure. Based on this information, Mosquito Barrier was found to be useful in reduction of mosquito bites, thus reducing disease.

For more information or to order Mosquito Barrier go to: http://www.mosquitobarrier.com

    Contact:
    William Anderson
    Caleb Treeze Organic Farm
    624 Ruberta Ave.
    Glendale, CA 91201-2335
    Phone: 818-247-9600
    Contact@MosquitoBarrier.com

'/>"/>

SOURCE Garlic Research Labs, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
3. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
4. Researchers at Cleveland Clinic Identify Site of Dysfunction in HDL, Carrier of Good Cholesterol
5. Video: New Research Discovers Independent Brain Networks Control Human Walking
6. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
7. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
8. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
9. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
10. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
11. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease